Holen Sie sich die Stockscreener-App
5.38
1.51%
0.08
Vorhandelsmarkt:
5.55
0.17
+3.16%
Savara Inc Aktie (SVRA) Neueste Nachrichten
Savara Announces New Employment Inducement Grant - Business Wire
How Investors Are Reacting To Savara (SVRA) Doubling Share Authorization And Reshaping Its CFO Role - simplywall.st
Savara shareholders approve share increases and executive changes at annual meeting - Investing.com UK
Savara (SVRA) Announces Leadership Changes in Finance Department - GuruFocus
Savara shareholders approve share increases and executive changes at annual meeting By Investing.com - Investing.com South Africa
Savara Expands Share Capital and Updates Executive Leadership - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Savara CFO Dave Lowrance steps down; COO Robert Lutz takes on CFO role amid leadership reshuffle - Pluang
Savara CFO Dave Lowrance to step down, Robert Lutz to expand role By Investing.com - Investing.com Australia
Savara CFO Dave Lowrance to step down, Robert Lutz to expand role - Investing.com Australia
Savara Announces Chief Financial And Administrative Officer Transition - TradingView
Savara: Lowrance Will Remain Available in Advisory Capacity >SVRA - Moomoo
Savara (SVRA) expands share capacity and appoints Robert Lutz as CFO/COO - Stock Titan
Savara Announces Chief Financial and Administrative Officer Transition - The Joplin Globe
Savara Inc. Announces Step Down of Dave Lowrance as Chief Administrative Officer, Effective July 15, 2026 - marketscreener.com
Assessing Savara (SVRA) Valuation As Shares Cool After Strong Long Term Returns - Yahoo Finance
SVRA News | SAVARA INC (NASDAQ:SVRA) - ChartMill
SVRA: All proposals, including director elections and plan amendments, were approved - TradingView
Oppenheimer Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Savara Reports Phase 3 Biomarker Gains for Rare Lung Disease - MyChesCo
SVRA Q1 2026 Earnings: EPS Misses Estimates by 9.17%, No Revenue ReportedDividend Growth Analysis - newsline.com
Savara Reports Long-Term Phase 3 Data Supporting Molgramostim Durability - MyChesCo
Savara Reports Phase 3 Data Showing Exercise Gains in Rare Lung Disease Trial - MyChesCo
Savara Inc. (SVRA) Q1 2026 Earnings: EPS Miss Reflects Investment Phase as Pipeline AdvancesGeographic Revenue Trends - newsline.com
SVRA Q1 2026 Earnings: Wider-than-Expected Loss but Stock Gains on Pipeline ProgressAnalyst Coverage Count - The Legal Advocate
SVRA Q1 2026 Earnings: EPS Misses Estimates as Company Reports No RevenueEarnings Revision Downgrade - newsline.com
SVRA Stock Price, Quote & Chart | SAVARA INC (NASDAQ:SVRA) - ChartMill
Savara Inc. (SVRA) Stock Price, News, Quote & History - Yahoo Finance
Savara Inc stock (US80633A1025): Jefferies conference appearance keeps rare-disease biotech in focus - AD HOC NEWS
SVRA Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues Pipeline DevelopmentAnalyst Coverage Count - thelegaladvocate.com
Rare lung disease biotech Savara heads to Jefferies investor conference - Stock Titan
Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference - The Joplin Globe
Savara: The Rare Disease Funnel Is Becoming A Commercial Asset (NASDAQ:SVRA) - Seeking Alpha
Savara Advances MOLBREEVI Toward FDA Decision as Loss Widens - MyChesCo
SVRA Q1 2026 Earnings: Wider Loss Amid Continued Pipeline DevelopmentEarnings Momentum Score - newsline.com
SVRA Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues Development - thelegaladvocate.com
New aPAP Phase 3 Data and Wider Losses Might Change The Case For Investing In Savara (SVRA) - simplywall.st
SVRA Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Navigates Pipeline CostsGuidance Update - thelegaladvocate.com
LifeSci Capital Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Savara Inc. (SVRA) Faces Modest Pullback as Shares Test Support Levels Near $5.00Sector Sentiment - The Legal Advocate
Savara Inc. (SVRA) Q1 2026 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Advances Pipeline - newsline.com
Savara Inc. (SVRA) Reports Q1 Financial Results - Insider Monkey
Wells Fargo Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Savara Inc stock (US80633A1025): fresh IMPALA?2 data at ATS 2026 keeps rare?disease bet in focus - AD HOC NEWS
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 20 - BioSpace
5 Best Penny Stocks to Buy for Long Term - Insider Monkey
Savara presents biomarker data from molgramostim trial at ATS By Investing.com - Investing.com South Africa
Savara presents biomarker data from molgramostim trial at ATS - Investing.com
Savara (SVRA) Reports New Clinical Findings at ATS 2026 Conferen - GuruFocus
2.60%
0.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):